Chimeric antigen receptor (CAR) T-cell therapy is a novel class of immunotherapy which involves genetically engineered T-cells to allow recognizing and targeting the tumor cell.
More Than 5 New CAR T Cell Therapies Are Expected To Be Approved In Next 10 Years Says Kuick Research
Global CAR T Cell Therapy Market & Clinical Trials Insight 2028 Report Highlights:
- Global CAR T Cell Therapy Market Opportunity > USD 15 Billion
- Global & Regional Market Insight: Current & Market Forecast 2028
- Emerging In Vivo Induced CAR T Cell Therapies
- CAR T Cell Therapy Approval & Reimbursement Scenario By Country
- Patent, Price, Sales Insight On Approved CAR T Cell Therapies
- Insight On More Than 600 CAR T Cell Therapies In Clinical Trials
- CAR T Cell Therapies Clinical Trials Insights by Company, Country & Phase
Download Report: https://www.kuickresearch.com/report-car-t-cell-therapy-market
Chimeric antigen receptor (CAR) T-cell therapy is a novel class of immunotherapy which involves genetically engineered T-cells to allow recognizing and targeting the tumor cell. During this therapy, T-cells from individual’s blood are separated and are genetically modified to express chimeric antigen receptor. Once infused back into patient, CAR enable the T-cell to recognize and attach to antigen on the cancer cell, thus causing its destruction. Currently, CD19 targeting CAR T cell therapy products are most widely used and have exhibit remarkable efficacy in patients with acute lymphoblastic leukemia, non-Hodgkin lymphoma, and other hematological cancers.
Since the approval of first CAR T-cell therapy product in 2017, several drugs including Kymriah, Yescarta, Tecartus, Abecma, and Breyanzi have entered the global market. Additionally, Relma-cel developed by JW Therapeutics has received NMPA approval in China. This is the first CAR T-product independently developed by China. Their promising results and robust sales have further initiated a large number of clinical trials in this segment. Currently, there are more than 900 studies worldwide which are using CAR T-cell therapy products as investigational drugs in wide range of cancers.
The extensive research activities in this sector has further enabled the development of bispecific CAR T-cell therapy products which have the ability to recognize two different target on the cancer cells, thus enhancing the efficacy and specificity in comparison to already approved products. Recently, US FDA has granted orphan drug designation to CT120 for the management of acute lymphoblastic leukemia. CT120 developed by IASO Biotherapeutics is a novel fully human CD19/CD22 dual-targeted chimeric antigen receptor (CAR)-T cell therapy. The cellular domain of CT120 consists of 2 fully human single-chain fragment variable sequences with the ability to specifically bind to CD19 and CD22. The novel drug represents first dual-targeted CAR T-cell therapy and is enter in market in forthcoming year.
The high cost of treatment is a key impediment to the adoption of the therapy. This hinders the clinical translation of the results of innovative therapeutic approaches in cancer immunology to benefit target populations. The industry key players in the market in partnership with government are working to reduce the cost of therapy. Apart from this, the industry key players have adopted strategic alliances including collaboration, partnerships, or mergers to maintain their position in the market. For instance, German oncology clinics have collaborated with Optima Pharma to create an automated manufacturing unit for decentralised production of CAR T-cell therapies in treatment centers. The major players in the market are Novartis, GGilead Science, Pfizer, Celegen Corporation, Bluebird Bio, and others which actively indulge in research and development to drive this sector.
The global CAR T-cell therapy market is expected to surpass US$ 15 Billion by 2028. Increasing emphasis on research & development therapies for cancers, such as lung cancer, colorectal cancer, multiple myeloma cancer, and prostate cancer, is likely to create significant growth opportunities CAR T-cell therapy providers. In addition to cancer, researchers are also validating the role of therapy in wide range of other diseases including HIV, autoimmune disorders, infections, and others which will further propel the growth of market during the forecast period.
Contact:
Neeraj Chawla
Kuick research
Research Head
+91-981410366
neeraj@kuickresearch.com
https://www.kuickresearch.com